Login
$LITS
$0.86 +$0.01 (1.16%) Live

$LITS 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Unregistered Sales of Equity Securities

As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) entered into an Advisory Agreement (the “Advisory Agreement”) with Green Dragon Investments LLC (“Green Dragon”), pursuant to which the Company agreed to pay G...

30 Jul 2026 8-K: Results of Operations and Financial Condition

Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred

24 Jul 2026 8-K: Regulation FD Disclosure

INVESTOR PRESENTATION The largest public equity vehicle built to provide accessibility to Litecoin July 2026 Nasdaq: LITS

13 May 2026 8-K: Results of Operations and Financial Condition

SAN DIEGO, CA, May 13, 2026 – Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Strategy” or the “Company”), the first U.S. public company to adopt Litecoin (LTC) as its primary treasury reserve asset, today announced financial results for the f...

17 Feb 2026 8-K: Results of Operations and Financial Condition

Second Quarter Performance Driven by Successful Deployment of Treasury Operations; Reflecting Commitment to Strategic Focus on Leveraging Litecoin Holdings Complemented by Disciplined Capital Allocation

12 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The Lite Strategy, Inc. 2026 Stock Omnibus Equity Compensation Plan (as amended from time to time, the “Plan”), maintained by Lite Strategy, Inc. authorizes the Compensation Committee to provide grants of equity compensation to Advisors,...

30 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

9920 Pacific Heights Blvd., Suite 150San Diego, CA 92121(858) 369-7100

05 Dec 2025 8-K: Changes in Registrant's Certifying Accountant

December 5, 2025Securities and Exchange Commission100 F Street, N.E.Washington, D.C. 20549-7561

18 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

As previously disclosed on the Current Report on Form 8-K filed with the SEC on July 22, 2024, the Board of Directors (the Board) of Lite Strategy, Inc. (the Company) previously appointed Justin J. File as the Acting Chief Executive Offi...

30 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Lite Strategy Announces $25M Share Repurchase Program, Signalling Shift From Initial Litecoin Accumulation to Active Capital Market Operations

15 Sep 2025 8-K: Unregistered Sales of Equity Securities

As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 6,022,869 shares of the Company’s Common Stock, par value $0.00000002 ...

10 Sep 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Regulation FD Disclosure

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS’

04 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

This Master Loan Agreement (the “Agreement”) is dated as of 3rd of September, 2025 by and between BitGo Prime, LLC (“BitGo,” “BitGo Prime,” or “Lender”), a limited liability company organized and existing under the laws of Delaware, and ...

06 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

On August 5, 2025, Steven D. Wood informed the board of directors (the “Board”) of MEI Pharma, Inc. (the “Company”) of his decision to resign as a director of the Company, effective immediately. Mr. Wood’s decision to resign from the Boa...

05 Aug 2025 8-K: Regulation FD Disclosure; Other Events

SAN DIEGO, 5 August 2025 – MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or “the Company”) today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury st...

30 Jul 2025 8-K: Unregistered Sales of Equity Securities

As previously reported, on July 22, 2025, the Company issued pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 6,022,869 shares of the Company’s Common Stock, par value $0.00000002 per share (the “Common S...

22 Jul 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more

MEI Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Titan Partners Group LLC, a division of American Capital Partners, L...

13 May 2025 8-K: Results of Operations and Financial Condition

SAN DIEGO--(BUSINESS WIRE) — May 13, 2025 – MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025.

07 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

11455 El Camino Real, Suite 250San Diego, CA 92130(858) 369-7100

12 Feb 2025 8-K: Results of Operations and Financial Condition

SAN DIEGO--(BUSINESS WIRE) — February 12, 2025 – MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support